A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging the company and certain executives and directors engaged in securities fraud and other unlawful business practices. The litigation follows the company’s disclosure that the FDA issued a Complete Response Letter for relacorilant’s New Drug Application in hypertension secondary to hypercortisolism, saying additional evidence of effectiveness was needed; Corcept shares fell 50.4% on December 31, 2025. Investors who purchased Corcept securities during the class period have until April 21, 2026, to seek appointment as lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603031402PRIMZONEFULLFEED9665119) on March 03, 2026, and is solely responsible for the information contained therein.